Section Arrow
ADTX.NASDAQ
- Aditxt Inc.
Quotes are at least 15-min delayed:2026/05/12 05:45 EDT
Pre Market
Last
 0.1081
-0.0011 (-1.01%)
Bid
0.1036
Ask
0.1081
High 0.1083 
Low 0.101 
Volume 25.49K 
Regular Hours (Closed)
Last
 0.1092
-0.0096 (-8.08%)
Day High 
0.11 
Prev. Close
0.1188 
1-M High
0.54 
Volume 
1.97M 
Bid
0.1036
Ask
0.1081
Day Low
0.098 
Open
0.1092 
1-M Low
0.1 
Market Cap 
107.45K 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.17 
20-SMA 0.27 
50-SMA 1.18 
52-W High 1,979.6696 
52-W Low 0.098 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-9,230.64/-93.53
Enterprise Value
450.35K
Balance Sheet
Book Value Per Share
6.20
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
3.20K
Operating Revenue Per Share
1.05
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ENSCEnsysce Biosciences0.382+0.0318+9.08%-- 
Pre Market 0.3125 -0.0695 -18.19%
GERNGeron Corp1.39------ 
Pre Market 1.41 +0.02 +1.44%
TRAWTraws Pharma Inc2.02-0.16-7.34%2.46PE
Pre Market 2.0133 -0.0067 -0.33%
MRNAModerna52.88-1.47-2.70%-- 
Pre Market 54.14 +1.26 +2.38%
IOVAIovance Biotherapeutics3.7+0.08+2.21%-- 
Pre Market 3.71 +0.01 +0.27%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues. The company operates in one segment, which is focused on the discovery and development of biopharmaceutical products.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.